Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation-Results from the LenaMain Trial (NCT00891384).
Amelie BoquoiAristoteles GiagounidisHartmut GoldschmidtMichael HeinschMathias J RummelNicolaus KrögerElias Karl MaiJudith StrapatsasRainer HaasGuido KobbePublished in: Cancers (2023)
High baseline scores were maintained throughout the trial without significant differences between the Len dosages, which supports continuous treatment with a dose tailored to patients' HR-QoL.